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1 Table and 3 Figures 25 
Table 1: Key properties of the updating methods 26 
Figure 1: Type I error rate as the number of studies or updates in a meta analysis increases. 27 
Figure 2: Cumulative meta-analysis of the peptic ulcer data. 28 
Figure 3: Applying the four sequential methods to the peptic ulcer meta-analysis  29 
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ABSTRACT 30 
A living systematic review (LSR) should keep the review current as new research evidence emerges. 31 
Any meta-analyses included in the review will also need updating as new material is identified. If the 32 
aim of the review is solely to present the best current evidence standard meta-analysis may be 33 
sufficient, provided reviewers are aware that results may change at later updates. If the review is used 34 
in a decision-making context, more caution may be needed. When using standard meta-analysis 35 
methods, the chance of incorrectly concluding that any updated meta-analysis is statistically 36 
significant when there is no effect (the type I error) increases rapidly as more updates are performed. 37 
Inaccurate estimation of any heterogeneity across studies may also lead to inappropriate conclusions. 38 
This paper considers four methods to avoid some of these statistical problems when updating meta-39 
analyses: two methods, that is, law of the iterated logarithm and the Shuster method control primarily 40 
for inflation of type I error and two other methods, that is, trial sequential analysis and sequential 41 
meta-analysis control for type I and II errors (failing to detect a genuine effect) and take account of 42 
heterogeneity. This paper compares the methods and considers how they could be applied to LSRs.  43 
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Box “What is new?” 44 
− Living systematic reviews will require updating of any included meta-analyses at each review 45 
update. 46 
− If a living systematic review is used as part of a decision-making process, the frequent updating 47 
of the meta-analysis could lead to inappropriate conclusions being drawn, due to an inflated 48 
risk of falsely concluding statistical significance (type I error). 49 
− Four statistical methods exist to avoid type I error inflation, and other statistical problems, 50 
that arise in repeated meta-analyses. 51 
− This paper gives an overview of these methods and how meta-analyses should be performed 52 
in a living systematic review. 53 
 54 
Box 1 Living systematic reviews 55 
− A systematic review which is continually updated, incorporating relevant new evidence as it 56 
becomes available 57 
− An approach to review updating not a formal review methodology 58 
− Can be applied to any type of review 59 
− Uses standard systematic review methods 60 
− Explicit and a priori commitment to a predetermined frequency of search and review updating 61 
 62 
Box 2 An example meta-analysis of peptic ulcer trials 63 
As an example of how the methods might be applied, we apply these methods to a meta-analysis of 64 
23 trials comparing endoscopic hemostasis to a control treatment for treatment of bleeding peptic 65 
ulcers23. This was originally used as an example to illustrate sequential meta-analysis19 but is applied 66 
to all methods here.  67 
A random-effects cumulative meta-analysis is shown in Fig. 2. This shows the results of the meta-68 
analysis if it were updated once for every new trial, from the first-published trial at the top, to the last, 69 
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at the bottom. Each row of the forest plot representing the meta-analysis of all trials up to that point. 70 
It can be seen that a conventionally statistically significant result is achieved once only four trials have 71 
been included. We compare this to applying the four methods considered, assuming we wish to 72 
control for the standard type I error rate of 5%. For trial sequential analysis and sequential meta-73 
analysis, we also assume we wish to have 90% power to detect a relative risk of 0.5 (which is that 74 
found from a meta-analysis of all the trials). In this example, we do not use the ‘‘approximate Bayes’’ 75 
heterogeneity estimation for sequential meta-analysis. 76 
Fig. 3 shows the results for the four methods, respectively, (A) trial sequential analysis, (B) sequential 77 
meta-analysis, (C) Shuster, and (D) law of the iterated logarithm. In each case, the red dots and line 78 
show the progress of the updated meta-analyses after adding each trial, starting at the third trial, since 79 
a random-effects meta-analysis of two trials cannot reliably estimate heterogeneity. The black lines 80 
show the stopping boundaries for each method. Trial sequential analysis and sequential meta-analysis 81 
cross both the boundary for demonstrating treatment benefit and the maximum required sample size 82 
or information boundary after 10 trials for trial sequential analysis and 11 for sequential meta-analysis, 83 
although trial sequential analysis just touches the boundary after 6 and 9 trials. This shows that the 84 
required information or sample size has been reached after 10 or 11 trials, so had this analysis been 85 
run as a living systematic review, updating could reasonably have been stopped or slowed at that 86 
point. The law of the iterated logarithm and the Shuster methods take longer to find in favor of the 87 
treatment, requiring 16 or 17 trials to cross a boundary. 88 
These analyses have been shown as if there were an update to the LSR after every new trial. If updates 89 
are less frequent, so multiple trials are added at each update, the analyses and their results are the 90 
same. It is currently conventional to display the results of trial sequential analysis and sequential meta-91 
analysis methods as if an update had been performed for every trial, but this is not required. All 92 
analyses were performed in R, and the code is available from the authors on request. Code for trial 93 
sequential analysis is also available from the project website24. 94 
 95 
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1 - BACKGROUND 96 
The key intention of a living systematic review (LSR, see Box 1), which differentiates it from a standard 97 
systematic review, is that it will be updated frequently, ideally as soon as any new relevant study is 98 
published or identified1-3. Over time the information available to be included may increase, requiring 99 
the review to be-updated to ensure it is presenting the best available evidence. In many updates, this 100 
will require updating one or more of the meta-analyses included in the review. 101 
There are two purposes for undertaking an LSR, which while subtly different have implications for the 102 
methods used to update meta-analyses. The first purpose is to present a summary of the evidence at 103 
the time of the most recent update. For this purpose, simply repeating each meta-analysis (whether 104 
fixed or random effects), adding the newly identified studies and presenting new forest plots and 105 
summary estimates, may be the most appropriate approach. All other components of the meta-106 
analyses such as assessment of heterogeneity, subgroup analysis, and investigations of reporting bias 107 
will also have to be updated and repeated. Provided the meta-analysis methods used are appropriate, 108 
this approach will give the best estimate of the effect of interest at that point in time4. However, both 109 
the reviewers and readers should be aware that the results may change at later updates, and findings 110 
may be highly uncertain if there are few studies or participants included in the analysis. 111 
Systematic reviews and meta-analyses are also used for clinical decision-making, guideline 112 
development, and reimbursement decisions. Typically, the level of credibility for the meta-analyses of 113 
many beneficial and harmful outcomes is considered before making recommendations for practice. 114 
An LSR in particular might be used to support the creation of ‘‘living guidelines’’5, in which the best 115 
available evidence about the benefits and harms of an intervention is used to inform frequently 116 
updated recommendations about the use of the intervention. The effect estimate from the meta-117 
analysis and its precision (or confidence interval) is one of the deciding factors in grading the existing 118 
evidence, and in this paper, we discuss the implications of continually or frequently updating meta-119 
analyses for the statistical precision of the summary effects. 120 
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In a meta-analysis of clinical trials, we may wish to determine if an experimental treatment is superior, 121 
inferior, or equivalent to a control treatment. If the review presents assessments of statistical 122 
significance with a conventional 95% confidence interval or a P-value of 0.05, then updating of the 123 
meta-analyses may overestimate the number of meta-analyses considered statistically significant. 124 
While each individual analysis has only a 5% chance of finding a statistically significant result when, in 125 
fact, there is none (type I error), the chance of finding a false statistical significant result in any one 126 
meta-analysis increases as we repeat these analyses with each review update6. 127 
As an example, consider a sequence of clinical trials of a new intervention compared to a control, with 128 
an updated meta-analysis conducted as soon as each new trial is published. Suppose that there is no 129 
true difference in effect between intervention groups on a particular outcome. In this circumstance, 130 
the type I error rate, of incorrectly getting a statistically significant result, rises rapidly with each new 131 
analysis, as shown in Fig. 1. Similarly, the confidence intervals that often accompany the summary 132 
effect will be too narrow if calculated using a conventional meta-analysis. Therefore, using 133 
assessments of statistical significance at any individual update of a meta-analysis carries a substantial 134 
risk of erroneously concluding that the new intervention is beneficial (or harmful). More formally, 135 
repeating a meta-analysis inflates the type I error. 136 
In an LSR, we may also wish to determine when there is sufficient evidence such that we can be 137 
confident there is no meaningful effect to detect (such as no important difference in effect between 138 
new intervention and the control). This should be achieved so that a type II error is avoided, that is, 139 
the error of failing to detect a genuine effect and so that no future update will detect any evidence of 140 
a clinically meaningful effect. In a clinical trial, we might select an effect size to identify, such as a 141 
minimal clinically meaningful effect, a statistical power to detect that effect (e.g., 80% or 90%) and 142 
calculate the required sample size for the trial. We might conclude that the true effect size is less than 143 
the clinically meaningful effect if no statistically significant result is found once the specified sample 144 
size has been reached7. A similar approach can be taken with meta-analyses, including those in an LSR. 145 
However, previous analyses have found that few meta-analyses ever reach a sufficient sample size8. 146 
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When an LSR is used only to summarize the best evidence on a topic over time, using standard meta-147 
analysis methods should be sufficient as the review is updated. However, if the LSR is being used to 148 
make decisions or readers will use it to do so, then we may wish to consider approaches to avoid 149 
inadvertent type I and II errors. This paper considers four methods that have been proposed to correct 150 
for these potential errors when updating a meta-analysis. While this paper focuses on LSRs, the same 151 
issues apply to all systematic reviews which may be updated. For example, Cochrane recommends 152 
that all Cochrane reviews be kept up to date, with revisions at least every 2 years if new trials have 153 
been published. 154 
 155 
2 - ANALYSIS METHODS FOR REPEATED META-ANALYSES 156 
Updating a meta-analysis has some similarities with interim analyses of clinical trials9-11. Interim 157 
analyses are often performed in trials so the trial can be stopped early if there is convincing evidence 158 
that the intervention is beneficial or harmful. Methods have been developed to avoid type I and II 159 
errors and produce robust conclusions for these trial sequential analyses. These methods have been 160 
adapted for the analysis of repeated meta-analyses and more recently for the updating of network 161 
meta-analysis. 162 
Heterogeneity is also of particular concern in repeated meta-analyses. Heterogeneity should be 163 
considered in any meta-analysis, but it cannot be estimated accurately with few studies, and its 164 
estimation may vary substantially as a meta-analysis is updated. Incorrect estimation of heterogeneity 165 
may affect the conclusions drawn if the level of variability across studies is overestimated or 166 
underestimated. Heterogeneity also affects the required sample size, as greater heterogeneity 167 
reduces statistical certainty in the evidence and so increases the sample size required to detect a 168 
specified effect size. 169 
 170 
 171 
 172 
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2.1 -Trial sequential analysis 173 
Trial sequential analysis seeks to control the type I error by ensuring that the cumulative type I error 174 
rate across all updates remains at the desired level (usually 5%). To do this, the method uses the 175 
principle of alpha spending, that is, penalizing the type I error rate (alpha) at each analysis12-14. To 176 
avoid type II error, a maximum required sample size to detect some assumed effect size is also 177 
specified. This sample size is calculated in the same way as if the meta-analysis was a single clinical 178 
trial, by setting a desired type I error, an assumed effect size, and the desired statistical power to 179 
detect that effect. 180 
In order to avoid inflated type I error prior to achieving the maximum sample size, alpha-spending 181 
boundaries are applied to the meta-analysis. In trial sequential analysis, the O’Brien-Fleming 182 
boundaries are applied to the sample size15. At each update of the meta-analysis, the Z score 183 
(estimated treatment effect divided by its standard error) is calculated. If this exceeds the upper alpha-184 
spending boundary, then the result can be considered conclusive. For example, in a clinical trial, this 185 
would lead to a conclusion that the experimental intervention was superior to the control. 186 
Correspondingly, if the Z score were less than the lower alpha-spending boundary, the experimental 187 
intervention is worse than the control. If the maximum sample size is exceeded without crossing an 188 
alpha-spending boundary, we would conclude that any effect of the intervention is less than the 189 
specified effect. Additional stopping boundaries can be added to test for futility, so the updating 190 
process can be stopped if it is unlikely that a meaningful effect will be found. 191 
Ideally, the assumed effect size would be the minimal clinically important effect size, as recommended 192 
by experts in the relevant field [16]. Alternatively, the effect size may be based on the trials currently 193 
in the meta-analysis. If this approach is used, it is recommended that only trials judged to be at low 194 
risk of bias be used to estimate the desired effect14. Heterogeneity across studies increases the sample 195 
size because it increases uncertainty in the effect estimates. It is therefore recommended that the 196 
sample size be adjusted for heterogeneity, using either some prespecified estimate of heterogeneity 197 
or the best current estimate of heterogeneity in the meta-analysis. In trial sequential analysis, the 198 
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heterogeneity adjustment is generally made using the D2 statistic, which is mathematically correct and 199 
produces a larger required sample size, although the more widely used I2 statistic may be used 200 
instead17. 201 
 202 
2.2 - Sequential meta-analysis 203 
Sequential meta-analysis, in a similar way to trial sequential analysis, uses methods adapted from 204 
sequential trial monitoring and applies them to a meta-analysis10. Sequential meta-analysis uses 205 
Whitehead’s sequential trial boundaries approach to control type I error inflation and also type II error 206 
(failing to detect a genuine effect)18,19. 207 
Sequential meta-analysis is based around calculating the cumulative Z score (the sum of the study 208 
effect estimates times their meta-analytic weights) and the cumulative statistical information V (the 209 
sum of the inverse of the study weights) at each update. A conclusive result is deemed to be achieved 210 
if the Z/V pair lies outside some prespecified boundary. For meta-analysis, a rectangular boundary is 211 
recommended, as this reduces the chance of crossing a boundary very early. Hence, if Z exceeds some 212 
boundary value ZMAX, then there is evidence of a beneficial effect (as when crossing an alpha-spending 213 
boundary in trial sequential analysis). If V exceeds a boundary VMAX, then the updating can be stopped 214 
as no conclusive result is ever likely to be found, as the maximum required statistical information or 215 
sample size has been reached. The ZMAX and VMAX values are calculated based on setting a desired type 216 
I error, an assumed effect size, and the desired statistical power to detect that effect. 217 
Sequential meta-analysis implicitly adjusts for heterogeneity because as heterogeneity increases, the 218 
information contained in the meta-analysis decreases. This means the cumulative information V can 219 
decrease between updates as well as increase. Sequential meta-analysis can also control for 220 
misestimation of heterogeneity using an ‘‘approximate Bayesian’’ approach19. The DerSimoniane – 221 
Laird estimate of heterogeneity used at each update of the random-effects meta-analysis is replaced 222 
by a weighted average of the DerSimonianeLaird estimate and a prior estimate of heterogeneity. If 223 
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this prior estimate is suitably large, the method can control for underestimation of heterogeneity (and 224 
consequent overestimation of statistical information) early in the updating process. 225 
 226 
2.3 - The Shuster method 227 
The Shuster method is a newer alternative to the above two methods, designed by Shuster and Neu20. 228 
This method also uses alpha-spending boundaries but with the more conservative Pocock boundaries 229 
used in place of the O’Brien-Fleming boundaries used in trial sequential analysis20. The Pocock 230 
boundaries were chosen as they are considered more robust to possible changes over time in the 231 
effect size and to the fact that the required sample size is estimated rather than known. 232 
Rather than a Z score, a modified t statistic is used. The result is only considered conclusive if the t 233 
statistic crosses the Pocock alpha-spending boundary. The method controls only for type I error 234 
inflation, so an assumed treatment effect and power are not required, and no sample size or statistical 235 
information estimate is needed. This method requires prespecifying the number of meta-analysis 236 
updates that will be performed. As this may not be known for an LSR, a reasonable guess will have to 237 
be made. 238 
The Shuster method makes no explicit adjustment for heterogeneity, but in a random-effects analysis, 239 
the t statistic is a function of heterogeneity, decreasing as heterogeneity increases. 240 
 241 
2.4 - Law of the iterated logarithm 242 
Unlike the preceding methods, the law of the iterated logarithm approach is not based on sequential 243 
trial analysis21,22. Instead, it seeks to adjust the usual Z statistic so that the desired type I error (e.g., 244 
5%) is maintained across all updates. To do this, the method utilizes the fact that a modified form of 245 
the conventional Z statistic can be constructed to be bounded as the sample size N tends to infinity: 246 
The law of the iterated logarithm approach therefore recommends replacing the standard Z statistic 247 
at update k with a similar penalized statistic which is bounded as the statistical information (inverse 248 
of the sum of the meta-analytic weights) increases: 249 
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The formulae also require a further penalty term λ in the denominator. For an appropriate choice of 250 
λ, we can ensure that this penalized statistic is bounded by some suitable value, such as 1.96 for a 251 
conventional 95% confidence interval. Comparing this penalized statistic to 1.96 ensures that the 252 
standard 5% type I error is maintained across updates. The suggested values of λ are 2 for analyses of 253 
odds ratios, risk ratios, and mean differences and 1.5 for risk differences21. As with the Shuster 254 
method, the law of the iterated logarithm method only controls for type I error inflation, so does not 255 
require specification of sample size, an assumed effect estimate, or power. As with the Shuster 256 
method, no explicit adjustment for heterogeneity is made, other than the impact on the adjusted Z 257 
statistic from heterogeneity when using a random-effects analysis. 258 
An application of the four methods to a meta-analysis of peptic ulcer trials is presented in Box 2. 259 
 260 
3 - METHODS FOR NETWORK META-ANALYSIS 261 
A multivariate extension of the alpha-spending boundaries method has been proposed for updating 262 
network meta-analysis under the assumption of consistency25. Despite the computational complexity 263 
in the presence of multiple interventions, the approach is essentially the same as in pairwise meta-264 
analysis. Relative treatment effects between the compared treatments need to be set so as to satisfy 265 
the consistency assumptions. Then successively, monitoring boundaries for a predefined level of 266 
power are calculated so that overall, the type I error is at the nominal level. Comparison-specific 267 
treatment effects are updated after a study is added to the network as it contributes indirect evidence. 268 
In the method presented by Nikolakopoulou et al., informative priors are used for heterogeneity 269 
throughout. 270 
Updating a network meta-analysis requires additional considerations. The addition of a trial examining 271 
a given comparison updates the treatment effects for all other treatment comparisons examined in 272 
the network. The assumption of consistency underlying this method needs to be reassessed after each 273 
update and the inflation of type I error needs to be controlled for in the inferences. In the early phases 274 
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of the network where few studies are included, estimation of inconsistency and heterogeneity will be 275 
problematic26. 276 
 277 
4 - COMMENTARY ON THE METHODS 278 
The key properties of each method are outlined in Table 1. Most of the methods for handling repeated 279 
meta-analysis are based on an analogy between repeating meta-analysis and sequential analysis of a 280 
single clinical trial. While this analogy is generally reasonable, it has some limitations because meta-281 
analyses are based on multiple studies and are not a single controlled trial. Heterogeneity between 282 
studies is an obvious key difference. In all methods, if a random-effects meta-analysis is used, the test 283 
score incorporates the extra uncertainty and decreases as heterogeneity increases. In sequential 284 
meta-analysis, the observed information decreases if the observed heterogeneity increases, and in 285 
trial sequential analysis, the required sample size is adjusted for heterogeneity, so will increase if 286 
heterogeneity increases. Neither law of the iterated logarithm nor the Shuster method makes any 287 
explicit adjustment for heterogeneity, other than its effect on the t statistic or adjusted Z statistic. 288 
Currently, only sequential meta-analysis accounts for poor estimation of heterogeneity, particularly 289 
when there are few studies, by using the approximate Bayesian adjustment. However, as this 290 
adjustment is essentially an alternative estimator for heterogeneity, it could, in principle, be used in 291 
any of the methods. 292 
The methods have been described here as reaching a conclusion when some specified boundary is 293 
crossed (as seen in Fig. 3). It is also possible to represent the methods in a conventional forest plot, as 294 
with the cumulative plot in Fig. 2. This is achieved by adjusting the conventional 95% confidence 295 
intervals using the stopping boundaries so that the adjusted confidence interval excludes the null 296 
value only if a stopping boundary is crossed. Trial sequential analysis-adjusted confidence intervals 297 
can be generated, and the principle has been illustrated elsewhere for the sequential meta-analysis 298 
method19 but can be similarly used for all four methods discussed here. 299 
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Although sequential meta-analysis and trial sequential analysis appear different on the surface, they 300 
are, in fact, based on the same underlying statistical theory of using O’Brien-Fleming alpha-spending 301 
boundaries to adjust the significance level required to judge that an effect is statistically significant. 302 
As such, the methods should, in principle, have similar properties, although results may differ in any 303 
particular meta-analysis27. 304 
The primary difference between the methods is that sequential meta-analysis is based on the required 305 
statistical information to detect a desired effect, whereas trial sequential analysis generally uses the 306 
required sample size. Sample size depends on properties of the studies, such as the risk of an event in 307 
the control group. This may vary across studies and its estimate may change as the meta-analysis is 308 
updated, and so, the required sample size may not be constant across updates. Sample size should 309 
also be adjusted for heterogeneity. This could be done using the estimated heterogeneity at the 310 
current update, in which case sample size may vary substantially between updates. Alternatively, 311 
some prior estimate of expected heterogeneity could be used, but the sample size may be 312 
inappropriate if this estimate does not reflect the observed heterogeneity. Using required statistical 313 
information instead (as in sequential meta-analysis) has the advantage that it is independent of the 314 
properties of the trials, and of the heterogeneity, so, it does not vary across updates and can be 315 
calculated before trials are identified (e.g., in the protocol). Statistical information is, however, more 316 
difficult to interpret than sample size, and the total information may decrease between updates if the 317 
heterogeneity increases substantially. Although trial sequential analysis generally uses the sample size 318 
in its calculations, it is possible to use statistical information instead without any change to the 319 
underlying method. 320 
As law of the iterated logarithm and the Shuster method control only for type I error inflation, they 321 
do not specify a required sample size or statistical information, nor a desired effect size or statistical 322 
power to detect it. This may make them simpler to implement as the stopping boundaries are not 323 
dependent on the properties of the studies included in the analysis or of external factors such as a 324 
clinically meaningful effect size. However, it does mean that these two methods have no stopping 325 
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conditions if there is no observable effect, so the methods cannot easily recommend that the updating 326 
of an LSR shall be stopped for futility. While trial sequential analysis and sequential meta-analysis do 327 
allow for stopping for futility, they require specification of a desired effect size, which may require 328 
specialist knowledge to determine and may be arbitrary or overestimate the true effect. 329 
The methods could also be used to make judgments about when to update the LSR and its meta-330 
analysis. Informally, if the current results are close to a stopping boundary, then an update might be 331 
needed soon, but if the results are a long way from a boundary, then it may be appropriate to wait 332 
longer. In the sequential meta-analysis and trial sequential analysis methods, it is possible to estimate 333 
how much statistical information or additional sample size might be needed before a boundary is 334 
crossed, and so, time future updates for when that level of information might become available from 335 
new trials. To our knowledge, these methods have not yet been used in this way so any use of these 336 
methods to plan future update should be cautious. Other methods for determining when and if a 337 
meta-analysis should be updated have been developed and could be used alongside the sequential 338 
methods considered here7,28,29. 339 
 340 
5 – CONCLUSIONS AND RECOMMENDATIONS 341 
The aim of an LSR is to provide the best available evidence to support decision-making by updating 342 
frequently, potentially as soon as a single relevant new study is identified. As with conventional 343 
approaches to updating, it is to be expected that the findings of the meta-analyses may change 344 
between updates and so reviewers should be suitably cautious when drawing conclusions from a 345 
meta-analysis in an LSR, particularly why n considering if a result is statistically significant. 346 
The methods discussed in this paper should, in principle, increase the chance that conclusions drawn 347 
from a repeated meta-analysis are robust. The use of these methods in LSRs could therefore help 348 
prevent reviewers and readers from drawing inappropriate conclusions about the effectiveness of 349 
interventions. If these methods are used in an LSR, they should be clearly set out in the review 350 
protocol, including specification of desired type I error, assumed effect size, and the desired statistical 351 
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power. All the methods considered have been shown to avoid type I error inflation, as demonstrated 352 
in simulation studies for each method, and, to a somewhat lesser extent, in practical application in 353 
real meta-analyses. While this paper has focused on LSRs, the need to avoid errors of interpretation 354 
applies to all meta-analyses that are updated, even if less frequently than in an LSR. If a meta-analysis 355 
receives only one or two updates, however, the type I error inflation is modest, and there may be less 356 
need for these methods. 357 
The frequent updating in LSRs may make them more resource intensive, expensive, and time-358 
consuming to perform than a conventional review which might be updated infrequently or never. 359 
Given this, it is likely that in any LSR, decisions will have to be made about when to perform updates 360 
and if regular updating could be made less frequent or stopped. A possible benefit of the methods is 361 
that they could provide guidance as to when ceasing to update an LSR, or reducing update frequency, 362 
is statistically justifiable. The high risk of type I error means that conventional statistical significance is 363 
unsuitable for this30. When a stopping boundary is crossed in the methods considered here, however, 364 
the conclusions of the analysis are unlikely (up to the specified type I error) to change at future 365 
updates. 366 
In an LSR, it would also be useful to know that updating could be stopped because no meaningful 367 
effect will ever be found. Reaching the maximum sample size or statistical information (without 368 
crossing any other boundary) in trial sequential analysis and sequential meta-analysis provides a 369 
possible means for making such a decision. It should be noted, however, that the properties of using 370 
these methods to decide on when and how to update an LSR has not yet been formally investigated. 371 
Heterogeneity across studies in a meta-analysis will always be of concern, particularly when there are 372 
few studies so any estimation of heterogeneity is uncertain. This is a particular issue in LSRs as 373 
misestimation of heterogeneity will lead to incorrect confidence intervals and wrong judgments about 374 
the required sample size or amount of statistical information contained in the analysis. The 375 
approximate Bayes estimation of heterogeneity used in sequential metaanalysis may help to prevent 376 
such misestimation when there are few studies. However, any meta-analysis in an LSR which shows a 377 
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statistically significant result based on few studies, little information, or where there is evidence of 378 
substantial heterogeneity should be treated with caution, and further updates considered. 379 
The methods described can correct for the statistical errors of type I and II errors, but they do not 380 
prevent other nonstatistical errors of analysis or interpretation. In particular, they do not correct for 381 
bias, and analysts should still consider the possibility of publication and selective reporting biases, as 382 
well as potential for bias due to including poor-quality studies. 383 
This paper has only considered applying the methods to a single outcome, but most LSRs will meta-384 
analyze multiple outcomes. Conclusions drawn from the LSR and decisions regarding stopping 385 
updating will, naturally, have to consider the findings across all outcomes and potentially on any 386 
subgroup analyses. The methods discussed here could potentially be used simultaneously on multiple 387 
outcomes, but the value of doing this is currently unclear. Similarly, all the methods are designed for 388 
the analyses of trials comparing interventions. How to avoid statistical errors when updating other 389 
types of review, such as in diagnostic test accuracy or prognostic testing, remains uncertain. 390 
Some issues relating to the use of these methods remain uncertain and require further research. These 391 
include how the methods behave for different effect metrics (mean differences, relative risk, risk 392 
difference), their properties when data are sparse or highly heterogeneous, and how robust methods 393 
are when a boundary is crossed. 394 
All the methods considered here are designed to achieve correct type I errors or P-values across 395 
repeated meta-analyses. Of course, making judgments about the value of an intervention based on 396 
the P-value alone is, rightly, widely criticized31. In any statistical analysis, it would be wrong to assume 397 
that an intervention is beneficial simply because a P-value of below 0.05 has been found. The same 398 
applies to sequential methods; when a boundary is crossed, the full evidence should be considered, 399 
including effect size, confidence intervals and heterogeneity, and the evidence from other outcomes 400 
or subgroups. The main purpose of these methods is, perhaps, not so much to demonstrate a 401 
beneficial effect as to avoid misinterpretation of conventional meta-analyses and confidence intervals 402 
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in LSRs where frequent updating means the risk of type I error is high and to guide the need for 403 
updating. 404 
 405 
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TABLE 478 
Table 1 479 
Key properties of the updating methods 480 
 481 
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FIGURES 483 
Figure 1  484 
Type I error rate as the number of studies or updates in a meta-analysis increases. 485 
 486 
  487 
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Figure 2  488 
Cumulative meta-analysis of the peptic ulcer data. Each row of the forest plot representing the meta-489 
analysis of all trials up to that point, as if it were updated once for every new trial, from the first-490 
published trial at the top, to the last, at the bottom. 491 
 492 
  493 
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Figure 3 494 
Applying the four sequential methods to the peptic ulcer meta-analysis. Results of updated meta-495 
analyses are shown for (A) trial sequential analysis, (B) sequential meta-analysis, (C) Shuster, and (D) 496 
law of the iterated logarithm. The red dots and line show the progress of the updated meta-analyses 497 
after adding each trial, starting at the third trial, since a random-effects meta-analysis of two trials 498 
cannot reliably estimate heterogeneity. The black lines show the stopping boundaries for each 499 
method. Trial sequential analysis plots the standard Z score against cumulative sample size. Sequential 500 
meta-analysis plots the cumulative Z score (the sum of the study effect estimates times their meta-501 
analytic weights) against the cumulative statistical information (the sum of the inverse of the study 502 
weights). Law of iterated logarithm plots the penalized Z score at each update or trial and the Shuster 503 
method, the adjusted t statistic at each update or trial. (For interpretation of the references to color 504 
in this figure legend, the reader is referred to the Web version of this article.) 505 
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